Relvar Ellipta is a once-daily dual combination treatment comprising fluticasone furoate, an inhaled corticosteroid and vilanterol, a long-acting beta2-agonist, in a single inhaler, the Ellipta.

AstraZeneca’s Symbicort inhaler accounts for most of its inhalation portfolio revenue, projected by GlobalData to generate a total $2.5bn in 2024. Meanwhile GSK's lead inhalers include Trelegy Ellipta ...